BioCentury
ARTICLE | Finance

Wave of biopharma listings on East Asian markets: Public Equity Report

Plus: Taysha parlays FDA update into a rarity, a follow-on financing. And more

May 31, 2025 12:51 AM UTC

A flurry of new listings in Hong Kong and South Korea is energizing Asia’s public equity markets. 

Tuesday marked the third listing of the year on the Hong Kong stock market’s 18A biotech chapter, with Pegbio Co. Ltd. (HKEX:2565) raising HK$300.8 million ($38.4 million) at $15.60 for a postmoney valuation of HK$6 billion. Pegbio’s shares fell 26% to HK$11.56 on its opening trading day; they finished the week at HK$10.20, down 34%. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article